BindingDB logo
myBDB logout

null

SMILES: Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1

InChI Key: InChIKey=WCTODNJGIAJWJX-WQMAXLQNSA-N

Find this compound or compounds like it in BindingDB or PDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 451793   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Activin receptor type-1 [172-499]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 9n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 6 ul. Dose-response curves were generated by ...


US Patent US10710980 (2020)

More data for this
Ligand-Target Pair
Bone morphogenetic protein receptor type-1A [198-525]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.30E+3n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 6 ul. Dose-response curves were generated by ...


US Patent US10710980 (2020)

More data for this
Ligand-Target Pair
Activin receptor type-1 [172-499]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 18n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1...


US Patent US10710980 (2020)

More data for this
Ligand-Target Pair
Activin receptor type-1 [172-499,R206H]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1...


US Patent US10710980 (2020)

More data for this
Ligand-Target Pair
Serine/threonine-protein kinase receptor R3 [166-493]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 130n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1...


US Patent US10710980 (2020)

More data for this
Ligand-Target Pair
TGF-beta receptor type-1 [162-503]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.40E+3n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1...


US Patent US10710980 (2020)

More data for this
Ligand-Target Pair
Bone morphogenetic protein receptor type-1B


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 3.00E+3n/an/an/an/an/an/a



NOVARTIS AG

US Patent


Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...


US Patent US10947218 (2021)

More data for this
Ligand-Target Pair
Activin receptor type-1 [172-499]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 9n/an/an/an/an/an/a



NOVARTIS AG

US Patent


Assay Description
A kinase selectivity panel which measures autophosphorylation using the ADP-Glo Kinase Assay (Promega, V9101) was set-up for wild-type ALK2 (aa172-49...


US Patent US10947218 (2021)

More data for this
Ligand-Target Pair
Bone morphogenetic protein receptor type-1A [198-525]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.30E+3n/an/an/an/an/an/a



NOVARTIS AG

US Patent


Assay Description
A kinase selectivity panel which measures autophosphorylation using the ADP-Glo Kinase Assay (Promega, V9101) was set-up for wild-type ALK2 (aa172-49...


US Patent US10947218 (2021)

More data for this
Ligand-Target Pair
Activin receptor type-1 [172-499]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 18n/an/an/an/an/an/a



NOVARTIS AG

US Patent


Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...


US Patent US10947218 (2021)

More data for this
Ligand-Target Pair
Activin receptor type-1 [172-499,R206H]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



NOVARTIS AG

US Patent


Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...


US Patent US10947218 (2021)

More data for this
Ligand-Target Pair
Serine/threonine-protein kinase receptor R3 [166-493]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 130n/an/an/an/an/an/a



NOVARTIS AG

US Patent


Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...


US Patent US10947218 (2021)

More data for this
Ligand-Target Pair
TGF-beta receptor type-1 [162-503]


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.40E+3n/an/an/an/an/an/a



NOVARTIS AG

US Patent


Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...


US Patent US10947218 (2021)

More data for this
Ligand-Target Pair
Bone morphogenetic protein receptor type-1B


(Homo sapiens (Human))
BDBM451793
PNG
(US10710980, Example 25 | US10947218, Example 25)
Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCC(F)(F)CC1 |r,wU:23.25,10.10,wD:25.27,13.14,(-4.21,6.43,;-2.88,5.66,;-1.54,6.43,;-.21,5.66,;-.21,4.12,;-1.54,3.35,;-2.88,4.12,;-4.21,3.35,;-5.54,4.12,;-4.21,1.81,;-5.7,1.42,;-6.1,-.07,;-7.58,-.47,;-8.67,.62,;-10.16,.22,;-8.27,2.11,;-6.79,2.5,;1.12,3.35,;1.12,1.81,;2.46,1.04,;3.79,1.81,;3.79,3.35,;2.46,4.12,;5.13,1.04,;5.29,2.58,;6.53,1.67,;7.56,.53,;6.79,-.81,;5.29,-.49,;7.42,-2.21,;6.51,-3.46,;7.14,-4.87,;8.67,-5.03,;9.3,-6.43,;10.16,-5.43,;9.58,-3.78,;8.95,-2.37,)|
Show InChI InChI=1S/C29H36F2N4O2/c30-29(31)11-9-23(10-12-29)35-16-21-14-28(21,17-35)20-3-1-18(2-4-20)19-13-25(26(32)33-15-19)27(37)34-22-5-7-24(36)8-6-22/h1-4,13,15,21-24,36H,5-12,14,16-17H2,(H2,32,33)(H,34,37)/t21-,22-,24-,28+/m1/s1
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 3.00E+3n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1...


US Patent US10710980 (2020)

More data for this
Ligand-Target Pair